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1. Abstract
Sex hormone-binding globulin (SHBG) is a plasma glycoprotein that binds androgens and
estrogens with high affinity. It is produced by hepatocytes and secreted into the blood, where it
regulates the biological activities of male and female sex steroids.
Unlike the human gene, shbg in rodents, such as rats and mice, is silent in the liver postnatally,
and the gene expression is mainly restricted to the testes. The testicular gene product is referred
to as the androgen binding protein (ABP), as it binds androgens with high affinity in the male
reproductive tract. Human testis produces alternative shbg products, the function(s) of which is
largely unknown.
To understand why shbg is expressed so differently in humans and rodents and to learn more
about the function of the gene product, several lines of transgenic mice carrying human shbg in
their genome were produced. These mice express the human gene in the liver and have appre-
ciable amounts of circulating SHBG in the blood. Although it was anticipated that the presence
of this high-affinity steroid binding protein would result in imbalances in free and bound sex
hormone levels, the reproductive performance of these mice was not compromised in any way.
The comparisons of the expression patterns of two human shbg transgenes with different amounts
of 5’-flanking sequences (~6 kb or ~0.85 kb) provided information about the regulatory mecha-
nisms that govern human shbg expression and regulation in vivo. Specifically, upstream se-
quences present only in the larger human shbg transgene contributed to sexual dimorphism of
SHBG levels in mouse plasma, while both transgenes were subject to the regulation by andro-
gens in the kidney. Furthermore, testicular shbg expression required additional upstream se-
quences and was predominantly driven by a separate promoter.
In humans, plasma SHBG levels are regulated by different physiological and pathological con-
ditions as well as nutrition and body mass. Hepatic SHBG production has also been studied in
cultured cells, but little is known about the transcriptional regulation of the gene. In vitro stud-
ies demonstrated that the proximal human shbg promoter (-137/+7) is active in cultured liver
cells and that it is regulated by an orphan steroid receptor, hepatocyte nuclear factor-4 (HNF-
4). In essence, HNF-4 seems to substitute for TATA-binding protein (TBP) in the recruitment
of transcription initiating complex to the human shbg promoter. Detailed promoter analyses
also revealed a putative silencer within the human shbg promoter. This silencer comprises, at
least in part, a TA-rich stretch and it may co-operate with a DNA element that binds a ubiqui-
tous transcription factor Sp1, or another related factor recognizing GC-rich sequences.
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2. Review of the literature
2.1 Sex Hormones
2.1.1 Introduction
Sex steroids are responsible for normal sexual development, and the establishment of second-
ary sexual characteristics of male and female reproductive organs. They also induce sexual
dimorphism in a number of other tissues, such as muscle, bone, liver, kidney, and brain. Being
small, fat-soluble molecules, their effects are far-reached from the site of biosynthesis, and
their actions are subject to strict regulation at multiple levels.
2.1.2 Biosynthesis
The biosynthesis of all steroid hormones begins with cleavage of the 6-carbon side chain of
cholesterol to yield the 21-carbon precursor pregnenolone. The enzymatic steps of the two
parallel routes that produce estrogens and androgens from pregnenolone have been well char-
acterized and are shown in figure 1. The steroid A-ring can be oxidized at any point from
pregnenolone to androstenediol, and the conversion of both androstenedione to testosterone
and estrone to estradiol by 17β-dehydroxysteroid dehydrogenase is reversible. Although the
steroidogenic enzymes are basically the same in the gonads of both genders, the steroid biosyn-
thesis is regulated by pulsatile release of pituitary gonadotrophins in males, as opposed to
cyclic release in females. The gonadotrophin secretion from the pituitary is also subject to
negative feedback regulation by gonadal steroids.
Testosterone biosynthesis takes place in the Leydig cells located in the interstitial compartment
between the seminiferous tubules in the testis. The synthesis and secretion of testosterone is
stimulated by luteinizing hormone (LH) derived from the anterior pituitary. Although testoster-
one itself is responsible for several androgen effects, its 5α-reduced metabolite, 5α-
dihydrotestosterone (DHT), is significantly more potent in some target organs, such as prostate
and seminal vesicles. Also, the conversion of testosterone to estrogens by aromatase occurs in
certain male tissues (i.e. brain and bone) to ensure a proper androgenic response.
In the ovary, thecal and granulosa cells synthesize testosterone and androstenedione, which are
the precursors for estradiol and estrone, respectively. Estrogen synthesis from androgens in
granulosa cells is catalyzed by aromatase. In addition to initiating the follicle development, the
cyclic release of follicle stimulating hormone (FSH) from the pituitary increases the aromatase
levels in the ovary. Subsequently, LH triggers the complete maturation of the follicle and in-
duces ovulation. Large amounts of estrogen and progesterone are secreted by the corpus lu-
teum derived from the ruptured follicle. Several estrogen responsive tissues, such as the breast
adipose tissue, also contain aromatase probably to ensure high local concentration of estrogen
in this tissue.
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Figure 1. The Biosynthesis of sex steroid hormones. Enzymes involved in the numbered steps are: 20,22-desmo-
lase (1), 17-hydroxylase (2), 17,20-desmolase (3), 17β-OH-steroid dehydrogenase (4), 3β-ol-dehydrogenase and
∆4,5-isomerase (5), 5α-reductase (6), 3α-reductase (7), and aromatase (8).
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2.1.3 Mechanisms of action
2.1.3.1 Classical pathway
A large body of data is available on steroid hormone effects through genomic actions mediated
by intracellular steroid receptors. This multistep process begins as the free steroid enters the
target cell presumably by passive diffusion. Inside the cell, the steroid is recognized and bound
by its receptor, and depending on the steroid and its cognate receptor, the binding occurs in the
cytoplasm or nucleus. Upon complex formation with a proper ligand, the receptor undergoes
conformational changes, which allow it to bind to specific DNA element and act as a transcrip-
tion factor. Subsequent transcriptional activation or repression of the target gene reflects the
effect of a given steroid hormone.
The nuclear receptor superfamily consists of structurally related proteins with distinct ligand
preferences, i.e. steroid and thyroid hormones, vitamin D
,
 and retinoids. Several nuclear recep-
tors with unidentified ligands also exist, and these are referred to as orphan receptors. The
receptor molecule is composed of three well-characterized functional domains; the N-terminal
hypervariable region that contains the transactivation domain, the middle region that possesses
the zinc-finger structure that recognizes and binds the DNA, and the C-terminal domain that is
responsible for the ligand binding (Mangelsdorf et al., 1995; Tsai and O’Malley, 1994) (Figure
2).
The DNA binding by nuclear receptors is not entirely specific, and there is significant conser-
vation among the hormone response elements (HRE). Generally the favored sequence contains
a direct or inverted imperfect repeat of 6 bases with variable number of spacing nucleotides.
While some of the nuclear receptors bind DNA exclusively as homodimers, several others can
also form heterodimers with other family members (Mangelsdorf et al., 1995; Tsai and O’Malley,
1994).
The binding to the response element involves chromatin remodeling as the entire eucaryotic
DNA is packaged in nucleosomes, which inhibit the initiation of transcription by general tran-
scription factors (Kingston et al., 1996; Felsenfeld, 1992). Nuclear receptors not only interact
with the general transcription machinery, but also with other sequence-specific transcription
factors present in the nucleus as well as with numerous putative coactivators and repressors,
which adds on to the diversity of nuclear receptor-mediated steroid hormone action (McKenna
et al., 1999).
Hormone antagonists, which also bind to the nuclear receptor with high affinity, specifically
block the modulation of target gene transcription by sex steroids. These include tamoxifen for
estradiol and bicalutamide for testosterone. By contrast, a non-steroidal compound, diethylstil-
bestrol (DES), acts as a very potent estrogen by binding to and activating the estrogen receptor
(Fuhrmann U et al., 1998).
Figure 2. Functional domains of nuclear receptors.
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2.1.3.2 Non-genomic actions
As the classical model cannot explain all steroid effects, alternative mechanisms for steroid
hormone action have been searched for. Perhaps the best-characterized system is the sperm
acrosomal reaction (acrosomal membrane fuses with sperm membrane), which can be stimu-
lated in vitro by human follicular fluid or progesterone alone. Blackmore et al. (1990, 1991) have
shown that progesterone induces a very rapid rise in intracellular Ca2+-levels in human sperm.
In addition to being an immediate response for progesterone, Ca2+-accumulation is also achieved
with steroid coupled with bovine serum albumin (BSA), thus unable to diffuse into cell. There-
fore, it seems likely that the effect is not mediated by a nuclear, but rather by a membrane
receptor for progesterone. Furthermore, synthetic progesterone agonists, which readily acti-
vate the cognate nuclear receptor, fail to mimic the effect in full, which suggests that these two
types of receptors differ also with respect to ligand preferences.
Sertoli cells, the male analog for granulosa cells, respond to testosterone by increasing the
intracellular calcium levels. In support of plasma membrane action, similar to the progesterone
effect on granulosa cells, even a BSA conjugated steroid is capable of triggering the calcium
increase (Gorczynska and Handelsman, 1995).
Several reports have identified binding sites for estradiol on target cells (Pietras and Szego,
1977, 1980; Bression et al., 1986). Estradiol also induces a rapid increase in intracellular cal-
cium in chicken and pig granulosa cells. An estrogen receptor antagonist, tamoxifen, does not
block the effect, nor does a potent estrogen agonist, DES, mimic it. The estrogen-induced
calcium increase is also resistant to RNA and protein synthesis inhibitors, actinomycin and
cycloheximide, respectively, both of which would block any genomic steroid effect (Morley et
al., 1992). In rat uterine cells, estrogen stimulates adenylate cyclase directly without prior RNA
or protein synthesis. This leads to the activation of a reporter gene that contains a cAMP re-
sponse element rather than an estrogen response element (Aronica et al., 1994).  The effect is
rather unique, since it is obtained with both estrogen agonist and antagonist.
In summary, several lines of evidence confirm that the classical pathway involving nuclear
receptors does not mediate all steroid effects. First, some of the primary effects are extremely
rapid, and they are independent of transcription and translation. Second, the molecules mediat-
ing these rapid effects have ligand preferences different from the nuclear receptors. Finally, the
responses occur even without the steroid molecule entering the cell, which is the requirement
for nuclear receptor binding.
2.2 Sex Hormone-binding Globulin (SHBG)
2.2.1 Introduction
In addition to being regulated at the levels of biosynthesis, metabolism, and their nuclear/
membrane receptors, steroid hormones are bound by specific transport proteins in plasma.
Unlike serum albumin, which reversibly occupies a significant fraction of steroids in blood,
these proteins bind steroids with high affinity and low capacity. Traditionally it was thought
that extracellular binding proteins merely regulate the bioavailability of steroid and other hor-
mones, but accumulating evidence suggests more complex mechanisms by which these mol-
ecules modulate hormone action (Hammond, 1990, 1995).
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2.2.2 SHBG/Androgen binding protein (ABP)
Sex hormone-binding globulin (SHBG) was first identified as a β-globulin that bound 17β-
estradiol and testosterone in human plasma (Rosenbaum et al., 1966; Kato and Horton, 1968;
Vermeulen and Verdonck, 1968; Rosner and Deakins, 1968; Lea and Stoa, 1972). By employ-
ing various biochemical methods, such as charcoal adsorption of testosterone (Lea and Stoa,
1972), Sephadex gel filtration (Kato and Horton, 1968; Vermeulen and Verdonck, 1968;
Pearlman and Crepy, 1967), equilibrium dialysis (Vermeulen and Verdonck, 1968; Lea and
Stoa, 1972), and electrophoresis (Rosenbaum et al., 1966; Kato and Horton, 1968; Rosner and
Deakins, 1968), several independent groups were able to demonstrate that this globulin in
human serum binds testosterone and estradiol with much higher affinity than purified serum
albumin, which was traditionally thought to be the main steroid transporter in plasma. It was
also found that in normal females, but not males, testosterone is predominantly bound to SHBG
(Rosner and Deakins, 1968; Lea and Stoa, 1972). Similar to several other plasma proteins,
human SHBG is produced in the liver (Khan et al., 1981; Hammond et al., 1989; Gershagen et
al., 1989) and secreted into blood where it serves as a modulator of sex steroid action.
An extracellular protein with high-affinity for androgens exists also in the male reproductive
tract of several species and is referred to as the androgen binding protein (ABP). This andro-
gen-binding activity, distinct from nuclear androgen receptor, was first identified in the cytoso-
lic preparations from the rat epididymis (Ritzen et al., 1971; Hansson, 1972). Subsequent ex-
periments revealed that the amount of epididymal ABP increases towards maturity (Weddington
et al., 1974), and when the flow of testicular fluid to epididymis is blocked, the androgen-
binding activity is significantly reduced in the epididymis with concomitant increase in the
testis (French and Ritzen, 1973; Danzo et al., 1974). Immunocytochemical studies on male rats
confirmed that ABP is made in the testis and is transported to and taken up by epithelial cells in
the caput epididymis (Pelliniemi et al., 1981; French and Ritzen, 1973; Feldman et al., 1981).
Human SHBG and rat ABP are both dimeric glycoproteins showing significant homology in
their structure as well as steroid-binding and immunological properties (Que and Petra, 1987;
Musto et al., 1980; Cheng and Musto, 1982; Joseph et al., 1987, 1985; Hammond et al., 1987;
Walsh et al., 1986; Reventos et al., 1988; Kotite et al., 1986), and it is now known that plasma
SHBG and testicular ABP are the same protein with different tissue origin; SHBG is synthe-
sized by hepatocytes (Khan et al., 1981) and ABP by Sertoli cells of the testis (Kierszenbaum
et al., 1980; Steinberger et al., 1975; Hagenas et al., 1975). Moreover, within a given species,
a single gene encodes both proteins (Que and Petra, 1987; Joseph et al., 1987, 1985; Walsh et
al., 1986; Reventos et al., 1988; Gershagen et al., 1987). This review mainly focuses on plasma
SHBG, and only some aspects concerning the testicular ABP are discussed.
2.2.3 Species distribution
An SHBG has been identified in the plasma of several species (Corvol and Bardin, 1973;
Renoir et al., 1980; Wenn et al., 1977) with somewhat varying steroid binding specificity.
Rodents, such as rats and mice do not have a circulating binding protein for androgens or
estrogens (Corvol and Bardin, 1973; Renoir et al., 1980; Rosner and Deakins, 1968; Ritzen et
al., 1971), and the SHBG in rabbit plasma binds only androgens (Rosner and Darmstadt, 1973).
Apparently, only in primates, SHBG has a high affinity for both androgens and estradiol (Siiteri
et al., 1982).
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2.2.4 Quantitative measurements
A commonly applied procedure to compare relative affinities of different steroids for SHBG
and to determine SHBG concentration in a plasma sample relies on dextran-coated charcoal to
adsorb non SHBG-bound labeled steroid in solution (Hammond and Lahteenmaki, 1983). In
such binding capacity assay (BCA), the competition for binding sites by different steroids and/
or non-specific tracer binding is assessed by adding excess of unlabelled steroid. A method
devised by Scatchard is then utilized to determine the number of steroid binding sites and
SHBG concentration in a given solution assuming that one SHBG dimer binds one steroid
molecule.
The liquid-phase immunoradiometric assay (SHBG IRMA) employs radio-iodinated mono-
clonal antibody to label SHBG that is also recognized by non-radioactive polyclonal antibody
in solution. Antibody-bound SHBG is subsequently collected by means of an immobilized
secondary antibody, and the SHBG concentration is calculated based on the recovered radioac-
tivity. This assay is two orders of magnitude more sensitive and correlates remarkably well
with BCA (Hammond et al., 1985).
2.2.5 Structure
2.2.5.1 Subunits and dimerization
The SHBG precursor polypeptide consists of a 29 amino acid hydrophobic leader sequence
followed by 373 residues with two disulfide bridges (Hammond et al., 1986, 1987, 1989; Walsh
et al., 1986). In plasma, human SHBG exists as a 90 kDa homodimer of two identical protomers.
The dimerization is required for high-affinity binding of a steroid that further stabilizes the
dimeric form of SHBG (Casali et al., 1990; Rosner et al., 1974). In addition to specific ste-
roids, divalent cations, although probably acting independently of the steroid ligand, enhance
efficient dimerization of SHBG (Rosner et al., 1974). The dimerization domain of SHBG has
been mapped by site-directed mutations and spans the amino acids 138-148 (Bocchinfuso and
Hammond, 1994).
2.2.5.2 Steroid binding
In spite of significant variations in steroid specificity between species, plasma SHBG generally
binds DHT with highest affinity, followed by testosterone and estradiol (Hammond and
Bocchinfuso, 1995; Cunningham et al., 1981). In essence, a 17β-OH group, and an electrone-
gative group at C-3 within a planar C-19 steroid are required for optimal binding (Hammond
and Bocchinfuso, 1995; Cunningham et al., 1981). The affinity of SHBG for testosterone and
DHT is similar to that of the intracellular androgen receptor (AR), but the complex off-rate is
much faster and SHBG does not bind several antiandrogens and antiestrogens, such as cypro-
terone or cyproterone-17-acetate and tamoxifen, respectively (Danzo and Eller, 1975). Rat
testicular ABP differs from human plasma SHBG with respect to the DHT complex half-life;
DHT dissociates approximately ten times faster from rat ABP than from human SHBG at 0oC,
and this difference suggests a functional divergence between these proteins in different species
(Schmidt et al., 1981).
Regions responsible for dimerization and steroid binding in SHBG overlap, and confirmation
that the steroid-binding region resides in the amino-terminal half of SHBG came from studies
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with chimeric proteins. The amino terminus of human SHBG was fused to the carboxyl terminus
of rat ABP by means of a hybrid cDNA expressed in cultured cells. The fusion protein recov-
ered from the culture medium had the same steroid binding properties as the wild-type human
SHBG (Bocchinfuso et al., 1992a). Furthermore, several amino acid substitutions at the amino-
terminal portion of human SHBG also interfere with the steroid binding. Specifically, methionine
at 139 and lysine at 143 seem to play a central role within the steroid binding pocket of SHBG
(Bocchinfuso and Hammond, 1994; Bocchinfuso et al., 1992a; Sui et al., 1992).
Affinity-labeling studies of SHBG have pinpointed amino acids that might be in direct contact
with the steroid ligand. However, two groups, which used [14C]17β-bromoacetoxy-DHT to
label the steroid-binding pocket in SHBG, identified different labeled residues. According to
one group, lysine at 134 was exposed to the alkylating reagent within the DHT derivative
(Namkung et al., 1990), whereas another group recovered histidine at 235 as a single labeled
amino acid (Khan and Rosner, 1990). Grenot et al. (1992) used tritiated androgen and estrogen
derivatives to photolabel SHBG, and their results pointed out methioneine at 139 as interacting
with both estradiol and testosterone.
2.2.5.3 Glycosylation
Each SHBG protomer has two sites for N-glycosylation and one site for O- glycosylation (Que
and Petra, 1987; Hammond et al., 1987; Avvakumov et al., 1983). The differential utilization
of these sites results in heterogeneity of the two protomers, which is seen as a presence of heavy
and light subunits in denaturing polyacrylamide gel electrophoresis (Danzo et al., 1989, 1991;
Danzo and Bell, 1988; Hammond et al., 1986). The functional significance of the attached
carbohydrates has been studied by site-directed mutagenesis and analysis of the glycosylation-
deficient mutants secreted into cell culture medium (Bocchinfuso et al., 1992b). The lack of
glycosylation does not influence SHBG’s steroid binding specificity or affinity for steroid ligands,
which suggests that the attached carbohydrates are not essential for dimerization of the two
subunits. When both N-linked carbohydrates are absent, less SHBG is secreted into culture
medium, but it has the same steroid binding properties as the wild-type protein (Bocchinfuso et
al., 1992b).
Power et al. (1992) have characterized a variant SHBG form due to polymorphism in the gene
encoding SHBG. This polymorphism introduces an additional N-linked glycosylation site at
residue 327, and when injected into rabbits, the variant SHBG has a reduced clearance rate as
compared to the wild-type molecule (Cousin et al., 1998, 1999).
2.2.5.4 Homology to other proteins
Human SHBG and rat ABP show no structural similarity to other steroid binding proteins, such
as the intracellular androgen and estrogen receptors (Bardin et al., 1988). They do, however,
resemble protein S, a vitamin K dependent modulator of blood clotting in plasma (Hessing,
1991; Joseph, 1997a). Protein S binds to C4b-binding protein that is involved in the comple-
ment system (He et al., 1997).  The most carboxyl-terminal part, which in most clotting factors
is a serine protease-like domain, is replaced by an SHBG/ABP-like domain in protein S
(Gershagen et al., 1987; Baker et al., 1987). This region is also homologous to the five globular
domains of laminin A chain (Joseph, 1997a). Laminins are multidomain proteins with multiple
functions; they participate in cell adhesion and differentiation, angiogenesis, tumor growth and
metastasis, and neurite outgrowth (Kleinman et al., 1993; Sasaki et al., 1988; Engel, 1992). Exten-
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sive sequence comparison has revealed domains in several other proteins that show significant
homology to SHBG and ABP. These include the G1 domain of agrin in neuromuscular junctions
(Patthy and Nikolics, 1993) and  merosin, a laminin-like protein with more restricted tissue
distribution (Ehrig et al., 1990).
2.2.5.5 Crystal structure
The amino-terminal portion of human SHBG has recently been crystallized in the presence of
DHT. The crystal structure of residues 1-205, containing one of the two laminin G-like do-
mains of SHBG, demonstrated the presence of two seven-stranded antiparallel β-sheets posi-
tioned on top of each other (Grishkovskaya et al., 1999; 2000). The steroid-binding pocket was
formed within this β-sandwich, as opposed to the α-helical ligand binding sites characterized
in nuclear steroid receptors (Tanenbaum et al., 1998; Pike et al., 1999). More specifically, the
contacts between the steroid ligand and SHBG are mediated mainly by hydrogen bonding
between serine 42 and the oxygen at the C3 position in the steroid A ring as well as hydrogen
bonds that may occur between the hydroxyl-group at C17 on the steroid D ring and asparagine
82 or aspartate 65. Other contact points with the steroid include phenylalanine 67, methionine
107, and methionine 139 (Grishkovskaya et al., 2000). The spherical G-domain of SHBG
shows no similarity to albumin or other extracellular steroid-binding proteins, but it is structur-
ally related to a set of functionally diverse proteins with known three-dimendional structure,
such as pentraxin, neuramidases, glucanases, and lectins. (Grishkovskaya et al., 2000).
2.2.6 Physiological functions
2.2.6.1 Plasma sex steroid carrier
Since SHBG in human plasma has a high affinity and low capacity for androgens and estradiol,
it is thought to regulate/influence the bioavailability and metabolic clearance of these steroids.
The metabolic clearance rate (MCR) for most sex steroids is inversely related to their affinity
for SHBG, i.e. both free and albumin bound steroids are irreversibly cleared from circulation,
while SHBG bound steroids are resistant to metabolic clearance (Siiteri et al., 1982; Petra et
al., 1985). For instance, androstenedione, which has a low affinity for SHBG, clears twice as
fast as testosterone from the human circulation, while both androstenedione and testosterone
have the same MCR within species with no plasma SHBG.
According to the free hormone hypothesis, only the unbound fraction of sex hormones is bio-
logically active, as free steroids are able to enter the target cells by simple diffusion (Mendel,
1989). In support of this hypothesis, the uptake of testosterone and DHT is significantly re-
duced by rat prostate glands cultured in the presence of human pregnancy serum, which con-
tains appreciable amounts of SHBG (Lasnitzki and Franklin, 1972, 1975). Also, Damassa et al.
(1991) have shown that an androgen-stimulated proliferation of a prostate cell line, LNCaP,
can be inhibited by adding SHBG to the culture medium. It has been further proposed that by
having a significantly higher affinity for testosterone than for estradiol and by being largely
occupied by testosterone in female plasma, SHBG could serve as an estrogen amplifier in
normal women (Burke and Anderson, 1972).
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The free hormone hypothesis with respect to extracellular steroid binding proteins has been
repeatedly challenged by several authors. For instance, considering the SHBG concentration
and the circulating amount of estradiol at any stage during the normal menstrual cycle in fe-
males, there would not be enough free steroid to fully occupy cellular estrogen receptors, which
is the requirement for maximal estrogen response (Siiteri et al., 1982; Wu et al., 1976; Pardridge,
1988). Furthermore, if the pool of free hormone accounted for all the actions of sex steroids, all
tissues would be exposed to the same hormone level (Pardridge, 1988). Pardridge has sug-
gested that also the SHBG-bound steroid is available to cells; SHBG could release the steroid
in the site of action and thereby amplify the steroid effect where needed (Pardridge, 1988)
(Figure 3).
2.2.6.2 Interaction with cell membranes
Since it is highly unlikely that specific and high affinity steroid-binding proteins in plasma
serve solely as reservoirs restricting hormone bioavailability and metabolic clearance, research
has focused on identifying other possible mechanisms of actions also for SHBG. One proposed
function involves specific receptors on cells of sex steroid target tissues. Estradiol-dependent
binding of SHBG has been detected on the membranes of human decidual endometrium
(Strel’chyonok et al., 1984; Avvakumov et al., 1986) indicating that SHBG selectively guides
sex steroids into the site of action. The endometrium-specific receptor has been solubilized and
partially characterized, and it seems to display two separate binding sites for SHBG (Fortunati
et al., 1992). As according to earlier studies (Strel’chyonok et al., 1984; Avvakumov et al.,
1986), the binding of SHBG to the solubilized receptor is specific and saturable, but the recep-
tor fails to recognize SHBG bound to any steroid ligand, including estradiol (Fortunati et al.,
1992). Specific receptors for SHBG have also been identified on other sex steroid dependent
tissues, including testis and prostate (Porto et al., 1992; Hryb et al., 1985, 1989; Frairia et al.,
1992).
In prostate cancer-derived LNCaP cells, the binding of a biologically active ligand to SHBG-
receptor complex causes the accumulation of intracellular cAMP (Nakhla et al., 1990). The
activation of adenylate cyclase within the cell is evoked by both estradiol and DHT, the strength
of response corresponding to the relative affinity of each ligand for SHBG. However, the in-
crease in cAMP levels is achieved only if SHBG is added to culture medium prior to the
addition of the steroid, which indicates that it is the unliganded SHBG that recognizes the
Figure 3. Tissue exposure to free and protein-bound steroid hormones. The free hormone hypothesis (a) states
that only the non protein-bound hormone is available to target cells, while according to bound hormone
hypothesis (b) specific steroid-binding proteins allow tissue-specificity and amplification of hormonal re-
sponses (adapted from Pardridge et al., 1988).
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receptor (Nakhla et al., 1990). A model proposes that only non steroid-bound SHBG recognizes
its receptor, and this binding is inhibited by any steroid ligand regardless of its biological
properties (as long as it binds SHBG). The binding of a proper ligand to receptor-SHBG com-
plex then induces a conformational change in SHBG, which triggers a second messenger cas-
cade eventually leading to elevated intracellular cAMP levels (Hryb et al., 1990; Nakhla et al.,
1990).
Nakhla et al. (1994) have shown that estradiol is able to increase intracellular cAMP levels in
the presence of SHBG also in human benign prostate hyperplasia (BPH) tissue. There are
several observations suggesting that SHBG mediates the signal leading to the activation of a
second messenger system. Firstly, antiestrogens do not block the response, which would be
the case if it was mediated through intracellular estrogen receptor. Secondly, diethylstilbestrol
(DES), a potent estrogen that does not bind to SHBG, fails to mimic the effects of estradiol.
Thirdly, DHT, which has a significantly higher affinity for SHBG than estradiol, blocks the
response probably by displacing the bound estradiol from SHBG. Thus, BPH tissue requires
estradiol for the activation of the secondary messenger system, as opposed to LNCaP cells,
which respond to both estrogens and androgens (Nakhla et al., 1990, 1994).
More detailed study of the SHBG receptor-mediated signaling system in prostate tissue sug-
gested that estradiol could, through SHBG, activate AR via a ligand-independent mechanism.
DHT stimulates the secretion of prostate specific antigen (PSA) by prostate tissue through
classical transcriptional activation mediated by AR (Riegman et al., 1991; Lee et al., 1995;
Henttu et al., 1992). Similar stimulation is achieved by estradiol in the presence of SHBG. As
with DHT alone, the estradiol-SHBG mediated stimulation is inhibited by antiandrogens, but
not by antiestrogens, which suggests that estrogen receptor (ER) does not mediate  this re-
sponse (Nakhla et al., 1997).
SHBG can also mediate the regulation of cell growth by estrogens and androgens. DHT and
estradiol stimulate, in the presence of SHBG, the growth of prostate carcinoma cells, and this
increased cell proliferation is associated with elevated cAMP levels inside the cell (Nakhla and
Rosner, 1996). By contrast, estrogen induced growth of MCF-7 breast cancer cells is inhibited
by SHBG (Fortunati et al., 1996). The reduction in growth rate is accompanied by intracellular
cAMP accumulation, which is absolutely dependent on both estradiol and SHBG. Therefore, it
seems unlikely that SHBG simply sequesters estradiol and restricts its availability to cells, but
may actually transmit the growth inhibitory signal to the cell nucleus.
Although SHBG seems to regulate intracellular signaling and cancer cell growth, such results
should be interpreted with caution. The LNCaP cells, for instance, are considered to be a poor
model for sex steroid action, as these cells contain a mutated androgen receptor. This mutated
receptor is also responsive to estrogens and anti-androgens resulting in significantly altered
genomic sex steroid effects (Veldscholte, et al. 1990).
SHBG does not exist exclusively in the plasma, but the interaction with a specific receptor
leads to internalization of SHBG by some cells. In Macaca nemestrina, immunoreactive SHBG
is localized in several cell types other than where the gene is expressed. These include prostate,
seminiferous tubules of the testis, and parenchymal cells in the liver (Bordin and Petra, 1980).
SHBG also enters cultured breast cancer and prostate cancer cells, MCF-7 and LNCaP, respec-
tively, via a mechanism that resembles receptor-mediated endocytosis (Bordin and Petra, 1980;
Porto et al., 1991; Nakhla et al., 1990). Moreover, i.v. injection of human SHBG into adult rats,
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which do not have circulating SHBG, leads to accumulation of estradiol and SHBG into uterus
and the epithelium of oviducts, (Noe et al., 1992).
Although there has been an inconsistency as to whether the steroid ligand is required in recep-
tor binding, it is widely accepted that the recognition of SHBG by cells is specific and satu-
rable, which is characteristic of receptor binding, and that these receptors are present only on
the cells of sex steroid responsive tissues (Frairia et al., 1992). The domain, which is respon-
sible for receptor binding in SHBG has been identified and spans the residues 48-57 (Khan et
al., 1990). Interestingly, this is the same region in SHBG that exhibits greatest sequence simi-
larity to the protein S carboxyl-terminus (Gershagen et al., 1987; Baker et al., 1987) that binds
the C4b-binding protein of the complement system (He et al., 1997).
2.2.6.3 Function in the male reproductive tract
Testicular ABP has been best characterized in rats because these rodents do not have plasma
SHBG (Corvol and Bardin, 1973), which could easily contaminate tissue preparations. ABP is
used as a marker of Sertoli cell function as its concentration varies upon hormonal stimulation
of the seminiferous tubules (Steinberger et al., 1975; Hansson et al., 1973; Kotite et al., 1978;
Sanborn et al., 1975; Ritzen et al., 1975; Hagenas et al., 1975) and at different spermatogenic
stages (Kierszenbaum et al., 1980; Anthony et al., 1984; Ritzen et al., 1982). The majority of
the ABP produced by Sertoli cells is secreted to the lumen of seminiferous tubules and is
transported to the epididymis where it is taken up by the epithelial cells (Gunsalus et al., 1981).
In the epididymis, testosterone-bound ABP probably serves to provide a proper androgenic
environment for maturing spermatozoa (Turner et al., 1984). One fifth of the synthesized ABP
is secreted into the blood, and during puberty, the levels of circulating ABP can be relatively
high in male rats (Gunsalus et al., 1981), but the significance of this circulating protein is not
known.
2.2.7 Gene structure and tissue-specific expression
The gene encoding human SHBG (shbg) is located in p12-p13 region of chromosome 17. It
contains eight exons separated by unusually small introns, with the entire coding region span-
ning only 3.2 kb of genomic DNA (Hammond et al., 1989).
Although an SHBG cDNA was initially cloned from a human liver library (Que and Petra,
1987), several testis-specific transcripts have since been identified (Hammond et al., 1989;
Gershagen et al., 1989). However, these testicular cDNAs are unusual reflecting alternative
splicing of the primary transcript in this tissue. One of the cDNAs cloned had a unique 5’-
sequence that corresponds to genomic shbg sequence found approximately 1.9 kb upstream of
the translation initiation codon for SHBG and encodes an alternative exon one. In the liver, the
first exon encodes the hydrophobic signal sequence for secretion. The testicular cDNA also
lacks 208 bp corresponding to exon 7, which results in premature termination of translation,
i.e. the last 118 amino acids are replaced by 9 different residues (Hammond et al., 1989). In
fact, none of the testicular cDNAs identified corresponded the full length SHBG secreted by
the liver. Interestingly, Alu sequences typical of human genomic DNA are found immediately
preceding the alternatively spliced exon sequences (Hammond et al., 1989), but whether these
repetitive sequences contribute to the alternative splicing is not currently known (Figure 4).
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Human shbg expression has also been demonstrated in several other tissues, including pla-
centa (Larrea et al., 1993), ovary (Misao et al., 1998a), uterine endometrium (Misao et al., 1994)
and myometrium, (Misao et al., 1997a) as well as in several breast cancer cell lines (Moore et al.,
1996). In addition to the normal SHBG mRNA, most of the tissues analyzed contained the
variant SHBG form lacking exon 7 sequence with a truncated 3’-end (Misao et al., 1997a,b,c;
1998a,b; Moore et al., 1996) identical to those characterized in human testis. The analyses of
the specific transcripts in normal and malignant tissues have shown that as the state of histo-
logical dedifferentiation advances, the relative amount of the variant SHBG mRNA increases
(Misao et al., 1998a,b). Also, in the ovary, the normal mRNA seems to be less abundant in
women after menopause (Misao et al., 1998a). In light of these studies, it has been proposed
that the balance between the normal and variant SHBG production is essential for the healthy
function and estrogen responsiveness of female reproductive organs. It is not known, however,
whether any of these alternatively spliced transcripts are translated to produce protein, and it is
thus difficult to speculate how the corresponding gene products might function.
Unlike the human gene, the rat shbg is not expressed in the liver postnatally (Corvol and Bardin,
1973; Renoir et al., 1980). However, rodents have circulating liver-derived SHBG in the fetus,
around the time when Wolffian ducts differentiate to male-specific reproductive organs, epid-
idymis and seminal vesicles (Sullivan et al., 1991; Becker and Iles, 1985). Immunoreactive
SHBG is also found in several other tissues of prenatal rat, and it has been proposed that fetal
SHBG not only delivers androgens to the site of action, but also protects other tissues from
excess androgen exposure (Becchis et al., 1996; Sullivan et al., 1991). The cDNAs for ABP/
SHBG have also been isolated from a rat brain library (Figure 4). However, similar to the
human testicular cDNAs, these represent alternatively spliced variants with alternative exon 1
sequences, and it is possible that separate promoters are responsible for shbg expression in
different rat tissues (Wang et al., 1990).
The sequences that flank human and rat shbg coding regions at the 5’-end, probably contribute
to differential expression patterns between species, but the exact regions responsible are yet to
be identified. Consistent with the expression pattern of the endogenous gene, mice transgenic
for rat shbg have abundant production of testicular ABP, and transcripts also exist in the brain,
but not in the liver (Joseph et al., 1997b; Larriba et al., 1995). Approximately 1.5 kb upstream
of the transcription start site are sufficient to maintain this tissue-specific expression pattern of
rat shbg in mice.
Figure 4. Alternative splicing of shbg. The eight exons that code for plasma SHBG and testicular ABP are num-
bered. Differentially utilized exons are shown as solid boxes, and alternative first exons utilized in human testis and
rat brain are alphabetized (adapted from Hammond and Bocchinfuso, 1996).
      brain                      testis exons encoding SHBG
 A       B      C      D           A B                                     1    2    3          4     5    6               7        8
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2.2.8 Regulation of plasma SHBG levels
2.2.8.1 Sex hormones
In humans, plasma SHBG levels are very low in both sexes at birth. During the first weeks of
life, they start to increase rapidly reaching a constant level around second or third month. At
prepuberty, even before the plasma levels of male and female sex steroids start to rise, SHBG
concentrations decline markedly in males and to a lesser extent in females. This sexual dimor-
phism is maintained until the sixth decade in men and postmenopause in women, after which
the levels increase slightly in males and further decrease in females (Anderson, 1974; Vermeulen,
1988).
During pregnancy, up to 7-fold increases in plasma SHBG levels occur. Also, oral administra-
tion of estrogens in both sexes leads to significantly increased plasma SHBG levels, which
return to the basal state after the treatment is stopped (Rosner and Deakins, 1968; Lea and Stoa,
1972; Anderson, 1974; Toscano et al., 1992; Vermeulen, 1988). The administration of human
chorionic gonadotrophin (hCG), which stimulates Leydig cell testosterone production, decreases
plasma SHBG in prepubertal boys, and pharmacological doses of pure androgen to both adult
males and females has similar but more subtle effects (Forest et al., 1988). However, SHBG
levels generally correlate poorly with androgens and estrogens in most physiological and patho-
logical conditions (Toscano et al., 1992).
Studies on human hepatoblastoma cells (HepG2), which synthesize and secrete SHBG into the
culture medium (Khan et al., 1981), also argue against the direct role of sex steroids in SHBG
production by the liver. In these cells, both androgens and estrogens increase (Loukovaara et
al., 1995a,b; Plymate et al., 1988) or, depending on the study, have no effect (Rosner et al.,
1984) on SHBG production. Furthermore, Loukovaara et al. (1995a,b) have shown that the
estrogen-induced increase in SHBG levels is more pronounced inside the cell than in the cul-
ture medium. They hypothesized that this increase might be mostly due to the enhanced pro-
duction of alternative transcripts and gene products that lack the secretion signal.
Although it seems unlikely that sex steroids affect plasma SHBG concentration by a direct
transcriptional mechanism, they may modify the carbohydrate composition of the two sub-
units. Indeed, there is a variation with respect to the number of bi- and tri-antennary type N-
linked oligosaccharides attached to SHBG subunits in males, females and pregnant females,
i.e. individuals with different estrogenic status (Danzo et al., 1991; Tardivel-Lacombe and
Degrelle, 1991). Ain et al. (1987) have also shown that estrogen-induced modulation of the
sialic acid content in thyroxine-binding globulin prolongs the half-life of this molecule (Ain et
al., 1987). Thus, sex steroids may exert their effects on plasma SHBG by regulating its clear-
ance from plasma (Joseph, 1994).
2.2.8.2 Nutrition and body mass
Fiber-enriched nutrition is known to increase SHBG levels in humans possibly by increasing
the amount of phytoestrogens (Adlercreutz et al., 1987). These isoflavonoid compounds have
shown to increase SHBG production also in HepG2 cells, but the effect is highly compound
dependent (Loukovaara et al., 1995c). By contrast, high fat diet has the opposite effect, and
SHBG levels correlate inversely with body mass and plasma triglyceride concentration (Reed
et al., 1987; Lapidus et al., 1986; Vermeulen, 1988). In men, there is also a positive correlation
           23
between SHBG levels and serum HDL as well as apolipoprotein A-1, which is the predominant
apoprotein associated with HDL (Hämäläinen et al., 1987). In a 12-year follow-up study, Lapidus
et al. (1986) demonstrated that among women with low plasma SHBG levels there is a higher
occurrence of cardiovascular disease and premature death. However, several other reports have
significant discrepancy with respect to the role of low SHBG as a risk factor in the develop-
ment of cardiovascular disease (Pugeat et al., 1995).
2.2.8.3 Insulin
Generally, adiposity also increases the pancreatic insulin production, and upper body obesity
increases the amount of free testosterone and decreases the clearance of insulin in the liver.
These increases in insulin and testosterone levels correlate negatively with plasma SHBG con-
centration (Peiris et al., 1989). However, the negative correlation between fasting plasma insu-
lin and SHBG levels in females (Peiris et al., 1989; Preziosi et al., 1993; Lindstedt et al., 1991)
is independent of androgens and body weight (Peiris et al., 1989). Unlike the sex steroids,
insulin correlates remarkably well with SHBG also in puberty and in several physiological
conditions (Toscano et al., 1992). This notion is employed to predict the occurrence of non-
insulin dependent diabetes (NIDDM) in females. In males, the situation is more complex and
apparently reverse in terms of the correlation of insulin and SHBG levels (Simon et al., 1992;
Haffner et al., 1993). In vitro studies on HepG2 cells also support insulin’s direct role in regu-
lating liver SHBG production. In these cells, insulin added to culture medium increases both
secreted and intracellular SHBG (Loukovaara et al., 1995b; Plymate et al., 1988).
2.2.8.4 Thyroid hormone
The relationship between SHBG and thyroid hormone levels in plasma is well-established
(Anderson, 1974). At a cellular level, thyroid hormone stimulates SHBG production in cul-
tured HepG2 cells in vitro (Rosner et al., 1984; Loukovaara et al., 1995b; Plymate et al., 1988).
Patients suffering from thyrotoxicosis have abnormally high thyroid hormone levels and ac-
cordingly enhanced hepatic SHBG production (Anderson, 1974). By contrast, in thyroid hor-
mone resistance (THR), in spite of abnormally high thyroid hormone levels, SHBG levels
remain normal and fail to rise when additional T3 is administered (de Nayer et al., 1986; Sarne
et al., 1988). SHBG is therefore a good marker for peripheral responses for thyroid hormone
and a valuable tool for distinguishing THR from thyrotoxicosis to avoid maltreatment (Sarne et
al., 1988).
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3. Aims of the present study
The expression of shbg is regulated differently in humans and rodents. While humans have
circulating plasma SHBG in adults, the predominant androgen-binding activity is found in the
male reproductive tract in rodents. This may reflect the functional differences between these
protein homologs, i.e. plasma SHBG and testicular ABP. In the present study, the following
questions were placed to elucidate the physiological function and regulation of plasma SHBG:
1) What are the requirements for the liver- and testis-specific expression of human shbg in
vivo?
2) What are the physiological consequences of SHBG production by adult rodent liver?
3) How is human shbg expression regulated in vivo during development and by hormones in
different tissues?
4) What are the factors that contribute to the hepatocyte-specific gene expression and thereby
govern the differences between the expression patterns of rodent and human genes?
4. Materials and Methods
Materials and methods that are described in detail in the original articles are listed in Table 1.
Only the procedures employed in additional unpublished studies are given below.
Antibodies. Antiserum against transcription factor Sp1 was purchased from Santa Cruz.
Plasmid constructions. To introduce human shbg sequence from +7 to +60 into -803/+7shbg
and -299/+60shbg fragments, a region spanning nucleotides from -41 to +60 was PCR-ampli-
fied using an 11 kbp genomic DNA fragment as the template (III). The forward primer spanned
human shbg nts -45/-22 and the reverse primer was complementary to nts +43/+60 with a
sequence (GAATGAAGCTT) for a HindIII site at its 5’-end. The PCR-product was digested
with  SmaI  and HindIII  and  linked to  nts -803/-41 of  the shbg promoter in  pSP72  (III).  The
-803/+60shbg and -299/+60shbg fragments were then subcloned into the XhoI/HindIII and
XbaI/HindIII sites of pGL2 Basic (Promega), respectively. Several 5’-deletion fragments of the
shbg promoter were also PCR-amplified from the 11 kbp DNA fragment. The forward primers for
these constructs corresponded to the following sequences relative to the shbg transcription
start site in the liver: nts -696/-679, -670/-650, -617/-596, -552/-531, -509/-489 and -458/-438.
Table 1. Materials and methods described in the original articles (I-III).
Experimental  procedure        Described in
Generation and characterization of transgenic mouse lines I
RNA analyses: northern blotting and primer extension I, II
in situ hybridization and immunohistochemistry I, II
Plasma SHBG and testosterone measurements I, II
Western blotting I, II
Surgical procedures and hormone treatments on mice II
in vitro DNase I footprinting and EMSA III
shbg-luciferase plasmid constructions III
Cell culture and transient transfection assays III
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In each case, a sequence (TGAACTCGAG) for an XhoI site was added to these primers for
subcloning. The reverse primer spanned human shbg nts -317/-290. PCR-products were di-
gested with XhoI and XbaI  and  subcloned  into pBluescript  KS- (Stratagene) for sequencing.
Human shbg region -803/-299 in  -803/+60pSP72 was replaced with each deletion fragment
followed by subcloning into pGL2 Basic as XhoI-HindIII fragments. As an exception, the shbg
fragments containing nts -509/-299 and -458/ -299 were subcloned directly into -803/+60pSP and
sequenced after subcloning the -509/+60 and -458/+60 fragments into pGL2 Basic. Human shbg
region -803/-299 was also excised from a 4 kbp genomic XhoI fragment in pBluescript KS- and
subcloned as a HindIII/XbaI fragment into pSELECT (Promega) for site-directed mutagenesis.
The AT-rich sequence within human shbg -803/-696 was removed using an oligonucleotide
complementary to nts -750/-675- excluding nts -727/-697. Sp1 site at position -526/-517 was
altered using the anti-sense Sp1 mutant EMSA oligonucleotide (see below).
In vitro DNaseI footprinting of human shbg -803/-299. Nuclear proteins from adult mouse
liver were extracted as described (III). Several human shbg region promoter probes were gen-
erated by digesting the -299/-803shbg fragment with HaeIII or HinfI. The following internal
fragments were chosen as probes:  -803/-656, -735/-585, -587/-360 and -541/-300. Fragments
were blunted and subcloned into EcoRV site of pBluescript KS- in such orientation that when
plasmid was linearized with HindIII, and end-labelled with the Klenow fragment of DNA
polymerase I and [α-32P]dCTP, the coding DNA strand contained the radioactive nucleotides.
After labelling, fragments were released from the plasmid and purified (III). Approximately
10 000 cpm of the labelled probe was used in an in vitro footprinting assay (III).
Nuclear extract preparation from cultured cells. Human hepatoblastoma HepG2 cells were
cultured as described (III). Nuclear extracts were prepared by scraping the cells from the plates
in PBS. All steps were performed on ice. After low-speed centrifugation, the cell pellets were
resuspended in 10 mM HEPES (pH 7.6), 1.5mM MgCl2, 10mM KCl, 1 mM DTT, and lysed by
passing them 10 times through a 22 gauge needle attached to a syringe. Nuclei were spun down
and resuspend in the same buffer followed by a centrifugation in an eppendorf centrifuge at full
speed. Nuclei were then resuspended in 20 mM HEPES (pH 7.6), 1.5 mM MgCl2, 420 mM
NaCl, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 25% glycerol and stirred at 0oC for 30
min. Lysed nuclei were spun down and the supernatant containing nuclear proteins was dialyzed
twice 2 hours in cold against 20 mM HEPES (pH 7.6), 1.5 mM MgCl2, 100 mM KCl, 0.2 mM
EDTA, 0.5 mM DTT and frozen in aliquots at -70 oC.
EMSA oligonucleotides. The following double-stranded oligonucleotides were also used as
radiolabeled probes and/or unlabelled competitors:
Human shbg -536/-511: 5’-gAAAAGACTGGGGGAGGAGTTCAGAC-3’
 3’-TTTTCTGACCCCCTCCTCAAGTCTGg-5’
Mutant shbg -536/-511: 5’-gAAAAGACTGGGTTAGGAGTTCAGAC-3’
 3’-TTTTCTGACCCAATCCTCAAGTCTGg-5’
Sp1 consensus: 5’-GCTGAGGGCGGGACCGCATC-3’
      3’-CGACTCCCGCCCTGGCGTAG-5’
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5. Results
5.1 Human shbg transgenic mice
5.1.1 Characterization of transgenic mouse lines (I and unpublished results)
Transgenes comprising the entire coding region of human shbg and either ~850 bp or  ~6 kb of
5’-flanking sequences were introduced into the mouse genome (I: Figure 1a). Microinjection
of these shbg fragments into oocytes yielded four DNA-positive founder animals when ana-
lyzed by PCR and subsequently by Southern blotting.
One of the founders carried a 11-kb shbg transgene incorporated into two distinct sites within
the genome as evidenced by three different genotypes transmitted to the progeny. F1 mice with
one of the two integration events were maintained as separate lines, and line shbg11-a (I:
Figure 1b) was predominantly used for further analysis.
One founder carrying a 4 kb human shbg transgene also transmitted two distinct genotypes to
the progeny, but strictly according to Mendelian inheritance typical of a single integration
event. Only a subset of the F1 animals carried the same genotype as the founder male, others
seemed to have lost copies of the transgene. More extensive Southern blot analysis revealed a
rearrangement of the most 3’ transgene copy in these animals resulting in the presence of only
one intact copy (not shown). The two distinct genotypes seemed to remain stable in F1 animals,
which were then used to establish two separate lines for further analyses (shbg4-b and shbg4-
c; I: Figure 1b).
The remaining two founders carrying 11 kb and 4 kb shbg transgenes, shbg11-b and shbg4-a,
respectively, had multiple transgene copies in one integration site. A Southern blot of all five
lines that were used for further analyses is shown in I: Figure 1b.
5.1.2 Tissue-specific expression of human shbg in mice (I)
Northern blot analysis of RNA extracted from five human shbg transgenic male mice, each
representing a separate line, demonstrated that both transgenes were active in the liver. In
addition, kidney displayed a strong expression of human shbg with the exception of line shbg4-
b, in which there was apparent loss of transgene copies and rearrangement in one of the two
remaining copies (I: Figure 2).
The 5’-sequences included only in the 11 kb human shbg transgenes were required for testis-
specific expression, as evidenced by almost undetectable levels of SHBG mRNA in the testes
of mice carrying the 4 kb transgenes (I: Figure 2).
5.1.3 Human shbg transcription start sites in different mouse tissues (I)
A radiolabelled oligonucleotide specific for exon 1 was used in primer extension analyses to
map the transcription start sites for human shbg in transgenic mice. The extension products
from liver and kidney RNA placed the major transcription start site 60 bp upstream of transla-
tion initiation codon in exon 1, while the same primer failed to anneal to shbg transcripts from
transgenic mouse testis (I: Figure 4). These results indicated that testicular shbg transcripts
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contained an alternative exon 1 sequence, and that an alternative promoter was possibly re-
sponsible for transcription in this tissue.
5.1.4 Alternative human shbg transcripts in mouse testis (I)
The lack of liver-specific exon 1 sequences in testicular human shbg transcripts was confirmed
by a northern blot analysis. As expected, these testicular transcripts failed to hybridize with a
probe consisting exclusively of exon 1 sequences, while mRNA isolated from transgenic mouse
liver and kidney readily hybridized with the same probe (I: Figure 3). Furthermore, while an
oligonucleotide complementary to exon 1 failed to anneal to the the testicular transcripts, exon
2 specific primer produced three products of different sizes in primer extension analysis (I:
Figure 5). This confirmed that a separate promoter located further upstream drives the tran-
scription of human shbg in transgenic mouse testis, and that the liver-specific exon 1 sequence
is replaced by an alternative exon.
5.1.5 Cellular localization of human SHBG mRNA and immunoreactive protein (I)
The cellular localization of human SHBG in various transgenic mouse tissues was studied by
immunohistochemistry.  In the liver, both human SHBG mRNA and protein localized in hepa-
tocytes, the signal being more pronounced in periportal lobes than in the close proximity to the
central vein (I: Figure 6a, b).
Immunoreactive SHBG was also found in the luminal surface of the epithelial cells that line the
proximal convoluted tubules in the kidney (I: Figure 6c) as well as in the interstitial compart-
ment in the testes of both shbg11 and shbg4 animals (I: Figure 6e,g). While the SHBG mRNA
co-localized with the protein in the kidney, it was present only in the Sertoli cells of transgenic
mice carrying the 11 kb human shbg transgene, consistent with the northern blot analyses (I:
Figure 6f,h). Moreover, human shbg expression in transgenic mouse testis appeared to vary
with respect to stage of spermatogenesis in each seminiferous tubule, being highest during
stages X-XII (I: Figure 7).
5.1.6 Human SHBG in mouse plasma and urine (I)
Production of SHBG by liver resulted in considerable amounts of steroid binding activity in
transgenic mouse plasma.  This lead to significantly increased amounts of testosterone in both
transgenic male and female mouse blood when compared to wild type littermates (I: Table 1).
Immunoreactive SHBG could also be detected in transgenic mouse urine with the exception of
shbg4-b mice that do not express the transgene in the kidney. Western blot and steroid binding
capacity assays demonstrated that SHBG in urine was structurally similar to the plasma protein
and possessed an intact steroid binding site (I: Figure 8).
5.1.7 Phenotypic analysis of human shbg transgenic mice (unpublished)
In spite of the presence of relatively very high concentrations of a binding protein for sex
steroids in their blood, shbg transgenic mice showed no obvious abnormalities with respect to
their reproductive performance. Also, male sperm counts and morphology appeared to be nor-
mal, and no gross abnormalities were observed in any other tissues examined by routine histol-
ogy. All five lines described have been bred to homozygosity with normal litter sizes and sex
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distribution within one litter.
5.2 Regulation of human shbg expression in transgenic mice during
development (II)
5.2.1 Human shbg expression in mouse fetus
In situ hybridization analyzes of 17.5 days post coitus embryonic sections demonstrated shbg
transcripts in shbg11 mouse liver and gut (II: Figure 1). Northern blotting was also used to
assess the liver-specific fetal shbg expression in wild-type and transgenic mice. Endogenous
mouse shbg expression was evident at the end of gestation with SHBG mRNA levels decreas-
ing towards perinatal period. By contrast, human shbg transgene expression increased in the
lines between embryonic day 17 and birth (II: Figure 2a). Immunoreactive mouse and human
SHBG could also be detected in the serum of both wild type and human shbg transgenic fetuses
(II: Figure 2b).
5.2.2 Serum SHBG levels during development
Liver-specific gene expression was mainly monitored on the basis of SHBG measured from
blood samples. Serum SHBG levels appeared to rise in both males and females during the first
20 days of life, after which the levels declined in females, as opposed to a further rise in males
(II: Figure 3a). This sexual dimorphism was accompanied by significant variability in blood
SHBG levels between individual animals. It appeared that by day 40, the sexual dimorphism
was achieved in full, and the variations among individuals in both sexes leveled off (II: Figure
3a).
Transgenic mice carrying the 4 kb human shbg transgene showed no such sexual dimorphism.
In shbg4-a mice, plasma SHBG levels rose steadily until day 60, after which they decreased
slightly (II: Figure 3b).
5.2.3 Correlation between serum SHBG and testosterone levels
In general, all transgenic mice had 10-100 times higher serum testosterone concentrations than
their wild-type littermates.  In both shbg11-a and shbg4-a males, serum testosterone levels
started to decrease after birth and remained low until 30 days of age. In females, serum test-
osterone levels also rose only after weaning age, i.e. in animals approaching puberty (II: Figure
4a-d). After puberty, significant variations in serum testosterone levels were obvious between
individual shbg mice (35nM-1.75µM in males), being consistently higher than in their wild type
littermates and correlating remarkably well with serum SHBG levels in both males and females.
5.2.4 Testis -specific human shbg expression during development
In human shbg11-a mice, transgene expression in the testis seemed to begin already before 10
days of age, and increased significantly as the animals reached sexual maturity by 30 days of
age (II: Figure 5). Therefore, it seems that human shbg is active in the mouse testis even before
blood testosterone levels start to rise.
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5.2.5 Effect of androgens on human shbg expression in mouse kidney
Kidney RNA was isolated from male and female mice of various ages in order to study kidney-
specific human shbg expression in transgenic mice. Northern blot analyses showed increase in
SHBG mRNA by day 20 in both sexes. Around day 40 in shbg4-a mice and day 20 in shbg11-
a mice, sexual dimorphic expression of shbg was observed (II: Figure 6). The higher amounts
of SHBG mRNA in male kidneys suggested that human shbg transgene expression was regu-
lated by male sex steroids.
To further elucidate the possible androgen dependence of human shbg expression in mouse
kidney, shbg11-a and shbg4-a male transgenic mice were castrated, and the SHBG mRNA
levels were compared to those of intact littermates. As expected, castration reduced the amount
of human SHBG mRNA in mouse kidney (II: Figure 7a), while no changes were observed in
plasma SHBG (not shown) and accordingly in liver-specific gene expression (II: Figure 7a).
To confirm that the SHBG induction in transgenic mouse kidney was a pure androgen re-
sponse, castrated males and ovariectomized females were treated with DHT. The hormone was
administered by subcutaneous injection of 100 µg daily dose of DHT in sesame oil for up to 5
days. Following steroid treatments, SHBG mRNA levels were increased in both sexes (II:
Figure 7 b-c).
5.3 In vitro characterization of human shbg liver-specific promoter (III)
5.3.1 Rodent and human shbg 5’-flanking regions
Despite obvious similarities between human and rat shbg 5’-flanking regions immediately up-
stream of liver and testis-specific exon 1, respectively, sequences with significant differences
also exist. Generally these differences represent DNA stretches in the human gene that are not
found in the rat gene (III: Figure 1).
5.3.2 Possible targets for transcription factor binding within the human shbg proxi-
mal promoter
To map important regions for liver-specific expression, the human shbg proximal promoter
spanning nucleotides from –299 to +7, relative to the transcription start site, was studied in
DNaseI footprinting assays. Several sites were specifically protected by nuclear proteins from
DNaseI-digestion and were likely to represent DNA regions that interact with transcription
factors involved in transcriptional activation or repression (III: Figure 2). The most pronounced
protections  were observed  in regions spanning nucleotides -41/-18 (FP1), -61/-52 (FP2), -88/
-66 (FP3), -114/-96 (FP4), -152/-134 (FP5), and -200/-177 (FP6).
5.3.3 Minimal promoter required for liver-specific transcription
To assess which of the DNA elements contribute to the basal expression of shbg in hepato-
cytes, series of deletion mutants were analyzed in human HepG2 hepatoblastoma cells. The
activity of a given deletion mutant was determined as its potential to drive transcription from a
luciferase reporter gene linked downstream of each mutant promoter. Transient transfection
assays in HepG2 cells revealed that the basal activity of human shbg promoter was achieved
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when four most proximal footprints were present, and that sequences upstream of -299 re-
pressed transcription (III: Figure 3).
5.3.4 Possible TATA-box within human shbg promoter
Both human and rat shbg genes have been characterized as TATA-less genes, since neither
contains a canonical TATA-box within a region immediately upstream of the tissue-specific
transcription start sites (Joseph et al., 1988). However, the sequence TTTAAC at –30 within
human shbg footprint 1 could serve as an atypical target for the TATA-binding protein, TBP. To
assess this possibility, the TTTAAC sequence was changed to TCCCAC, because this was
expected to abolish any binding of TBP to this element and to reduce the promoter activity. The
activity of the mutated –137/+7shbg fragment was indeed significantly lower than that of the
wild type promoter (III: Figure 4a), which suggested that the TTTAAC sequence is crucial for
efficient transcription initiation.
On the other hand, if TBP binds to human shbg footprint 1 (FP1), by converting the TTTAAC
to an optimal TATA-sequence, TATAAA, one should be able to increase the promoter activity
(Wiley et al., 1992). Interestingly, this mutation had a favorable effect on the promoter activity
in HeLa, but not in HepG2 cells (III: Figure 4a), and it was concluded that a factor other than
TBP recognizes the shbg promoter element, which is necessary for basal transcription in
hepatoma cells.
5.3.5 Orphan receptors COUP-TF and HNF-4 bind to human shbg promoter
In addition to a TATA-like sequence, FP1 contains stretches that resemble binding sites for
several liver-specific transcription factors. These include hepatocyte nuclear factors 1 and 4,
HNF-1 and HNF-4, respectively. Since an unlabelled competitor oligonucleotide correspond-
ing consensus HNF-1 element failed to displace the bound complex from labeled FP1 oligo in
an EMSA (not shown), the possible involvement of HNF-1 in shbg regulation was not studied
further.
While FP1 (5’-GGGCAACCTTTAACCCT-3’) showed a rather weak consensus sequence for
orphan receptor HNF-4, a site further upstream within FP3 (GGGTCAAGGGTCA), displayed
a significant homology to the chicken ovalbumin upstream promoter transcription factor, COUP-
TF, target sequence (Leng et al., 1996).
DNA-protein interactions at FP1 and FP3 were studied in EMSAs, which showed that the same
protein complexes recognize both FP1 and FP3 (III: Figure 5). Furthermore, antibody supershift
analyses demonstrated that these complexes consist of HNF-4 and COUP-TF in different ra-
tios. It appeared that FP1 is predominantly occupied by COUP-TF in vitro, while FP3 is more
or less equally bound by both factors (III: Figure 6).
5.3.6 Site-specific mutations at FP1 and FP3 reduce human shbg promoter activity
Since elements within the human shbg proximal promoter bind a liver-specific factor, HNF-4,
it was anticipated that mutations at these sites would severely compromise the promoter activ-
ity in hepatoma cells, as was already shown for FP1. The effect of site-specific mutations
within FP1 and FP3 (III: Figure 7a) was analyzed in DNaseI protection and transient transfec-
tion assays. When the mutations were studied individually and in combination, it was evident
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that the DNA-protein interactions were severely impaired at FP1 and FP3 as compared to the
wild-type shbg fragment (III: Figure 7b). It was also evident that the COUP-TF/HNF-4 site
within FP1 had a major role in transcriptional activation when compared to the one within FP3.
The disruption of both sites led to reduction of promoter activity by more than 70% (III: Figure
7c).
5.3.7 Transactivation of human shbg promoter by HNF-4 is antagonized by COUP-
TF
The potential of COUP-TF and HNF-4 to induce transactivation of human shbg promoter was
further studied in cotransfection assays. While significant transactivation of human shbg wild-
type promoter accompanied HNF-4 overexpression, the effect of COUP-TF was very moder-
ate (III: Figure 8). In fact, COUP-TF overexpression efficiently blocked the transactivation by
HNF-4.
The transactivation was efficiently abolished by mutations within COUP-TF/HNF-4 sites, again
FP1 showing a more crucial role in mediating HNF-4 effects. The cotransfection experiments
were also performed in HeLa cells, which have endogenous COUP-TF, but not HNF-4. The
effect of HNF-4 on the human shbg promoter activity was reproduced also in this cell line, but
was somewhat less pronounced than that observed in HepG2 cells (III: Figure 8).
5.3.8 Optimal COUP-TF site within FP1
To further study the role of TBP and the liver-specific factor, HNF-4, in mediating transcrip-
tional activation of shbg, the TTTAAC within FP1 was changed by site directed mutagenesis to
an optimal COUP-TF/HNF-4 binding site identified within FP3 (GGGTCAAGGGTCA). The
mutation distorted any resemblance of this site to TATA-box and should prevent the binding of
TBP while enhancing the binding of HNF-4 to FP1. When studied in the context of a reporter
gene in HepG2 cells, the optimal COUP-TF/HNF-4 site within FP1 did not reduce the pro-
moter activity (III: Figure 9). This suggested that the binding of HNF-4 or COUP-TF to the
region around -30, where the TATA-box is generally located, is favorable for the activation of
human shbg in liver cells.
5.4 Putative silencer in the human shbg promoter (unpublished)
Since a 4 kb human shbg transgene comprising 803 bp upstream of transcription start site was
shown to be very active in transgenic mouse liver and kidney, the repression by the region
upstream of –299 observed in vitro was somewhat surprising. The effect of this region on the
human shbg promoter activity was confirmed in the context of fragments that extended down to
translation start site (+60, III). Surprisingly, the 5’-UTR increased the promoter activity when
-299 nts upstream of human shbg liver-specific transcription start site were included, whereas
in the context of the -803/+60shbg promoter, reporter gene expression was dramatically re-
duced (Figure 5). As a result, the activity of -803/+60shbg was lower than -803/+7shbg and
only approximately 2-fold higher than the promoterless pGL2 Basic.
5.4.1 Characterization of the human shbg region -803/-299.
To map the putative silencer located upstream of –299 within the human shbg promoter, four
internal probes covering the entire human shbg region -803/-299 were used in in vitro footprinting
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assays, and in these assays, numerous possible binding sites for mouse liver nuclear proteins
were observed (Fig 6a-d). Transcription factor search database MatInspector version 2.1 (Quandt
et al., 1995) identified several putative binding sites for C/EBPβ as well as a putative Sp1 site
within footprinted region -536/-511.
5.4.2 Human shbg region –536/-511 binds ubiquitous factor Sp1
Of the footprints shown in figure 5, the one spanning nucleotides -536/-511 contains a se-
quence that resembles the consensus binding site (-526/-517: 5’-GGGGAGGAGT-3’) for a
ubiquitous transcription factor Sp1 (Quandt et al., 1995). EMSA showed the complexes that
form between human shbg region -536/-511 and nuclear proteins isolated from HepG2 cells
(Figure 7a; lane 2), and these complexes could be competed for by both specific competitor
(Figure 7a; lanes 3-4) and a consensus Sp1 oligonucleotide (Figure 7a; lanes 5-6), but not with
a COUP-TF oligonucleotide (III) (Figure 7a; lanes 7-8). Furthermore, an antibody against Sp1
supershifted a complex that formed between human shbg region -536/-511 and nuclear pro-
teins (Figure 7b, lane 3).
5.4.3 Mutation within the Sp1 site partially recovers human shbg promoter activity
To study the function of the Sp1 binding site identified in figure 6, mutations were introduced
to this region and tested in an EMSA (Figure 7c). The sequence GGGGAGGAGT was altered
to GGTTAGGAGT since this abolished the binding of Sp1 (Xie et al., 1997). The mutated
oligonucleotide did not compete for the wild-type oligonucleotide (Figure 7c; lanes 5-6) and
when labeled, its mobility was not retarded by nuclear proteins (Figure 7c; lane 7). The same
mutations were then introduced into the -803/+60shbg fragment and the effect on transcription
analyzed in a transient transfection in HepG2 cells. When compared to the wild type -803/
+60shbg, the mutation within the Sp1 site partially recovered the promoter activity (Figure 7d).
This suggests that the Sp1 site does not repress the human shbg promoter activity on its own,
but is likely to be required for the suppression by region -803/-299.
Figure 5. Identification of a putative silencer in the human shbg promoter. HepG2 cells were transfected with
human shbg promoter-reporter constructs and a pCMVlacz plasmid as an internal control for transfection efficiency.
The transcriptional activity (means ±  S.D.) of each construct is indicated relative to the activity of -299/+7shbg.
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Figure 6. DNaseI footprinting of transcriptional regulatory elements within human shbg 803/-299. An end-
labelled probe spanning human shbg -803/-656 (a), -735/-585 (b),  -587/-360 (c), or -541/-300 (d) was incubated
with increasing amounts of mouse liver nuclear extract (lanes 3 and 4) followed by digestion with DNaseI. Lane 2 is
without the addition of nuclear proteins. Maxam-Gilbert A/G-sequencing (lane1) is shown as a marker to define the
boundaries of each footprinted region (shown in brackets).
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Figure 7. Sp1-binding site within human shbg promoter represses transcription. a, double-stranded, end-la-
belled oligonucleotide spanning human shbg -536/-511 was incubated with 2 µg HepG2 nuclear proteins in the
absence (lane 2) or presence of specific (lane 3-6) or non-specific (lanes 7-8) competitors. Free probe was separated
from the protein-DNA complexes by non-denaturing polyacrylamide gel electrophoresis. b, antibody supershift was
performed by adding antiserum against Sp1 (lane 3) or normal rabbit serum (lane 2). c, double-stranded labelled
human shbg -536/-511 oligonucleotide (lanes 1-6) was incubated with 4 µg HepG2 nuclear proteins in the absence
(lane 2) or presence of excess wild-type (lanes 3-4) or mutant (lanes 5-6) competitor oligonucleotide. Lanes 1 in a, b,
and c, and lane 7 in c are without the addition of nuclear proteins. d, HepG2 cells were transfected with wild-type and
mutant -803/+60shbg-luciferase constructs together with a pCMVlacz plasmid as an internal control for transfection
efficiency. The activity of the mutant fragment (mean ± S.D.) is indicated relative to the activity of the wild-type
promoter.
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Figure 8. Detailed mapping of the silencer within human shbg promoter. The human shbg promoter deletion
mutants were fused to a luciferase reporter gene. The positions of the footprints identified in figure 6 are indicated as
shaded and the TA-rich strech as black boxes, respectively. HepG2 cells were transfected with each promoter-re-
porter plasmid together with a pCMVlacz plasmid as an internal control for transfection efficiency. The transcrip-
tional activity (mean ±  S.D.) of each promoter deletion mutant is indicated relative to the luciferase activity of -803/
+60shbg.
5.4.4 Analysis of human shbg -803/-299 deletion fragments
To identify the human shbg region responsible for the strong repression of transcription within
-803/+60shbg, several promoter deletions with 5’-ends based on the possible protein binding
sites were constructed. Promoter deletion fragments in front of a luciferase reporter gene were
analyzed in HepG2 cells, and the first suppressor appeared to be located between nts -299 and
-458, while further deletions seemed to have only moderate effects if any on the promoter
activity (Figure 8). The most predominant repression occurred when sequences -803/-670 were
added. This region contains a part of an Alu sequence (Hammond et al., 1989) including a
TAAAA-sequence which is repeated five times.
5.4.5 Removal of AT-rich sequence at -727/-697 partially recovers human shbg pro-
moter activity
To study the effect of the six TAAAA repeats within -727/-697 on human shbg promoter activ-
ity, the -803/+60shbg promoter was modified by site-directed mutagenesis system using an
oligonucleotide lacking the AT-rich stretch. Deleted sequence was analyzed by MatInspector
(Quandt et al., 1995), to confirm that the change did not introduce potential binding sites for
transcriptional regulators that might affect the promoter activity. Transient transfection in HepG2
cells (Figure 9) showed that the activity of -803/+60shbg was partially recovered and corre-
sponded to the activity of -670/+60shbg (Fig 8). Thus, the AT-rich sequence within -803/-696
is at least partially responsible for the reduced activity of the -803/+60shbg fragment.
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Figure 9. The effect of the TA-rich strech at 727/-697  on
the transcriptional activity of human shbg promoter.
HepG2 cells were transfected with wild-type and mutant
human shbg -803/+60luciferase constructs together with a
pCMVlacz plasmid as an internal control for transfection
efficiency. The activity of the mutant fragment (mean ± S.D.)
is indicated relative to the activity of the wild-type promoter.
6. Discussion
6.1 Tissue-specific expression of human shbg
6.1.1 Regulation of serum SHBG levels
In humans, SHBG is produced by the liver and secreted into the blood, where it binds andro-
gens and estrogens with high affinity. Unlike the human gene, shbg in rats and mice is silent in
the liver postnatally (Joseph, 1994). However, the incorporation of the human gene into the
mouse genome results in SHBG production by adult mouse liver and kidney. Furthermore, the
present study shows that all the elements required for the liver-specific gene expression are
included in the 4 kb human shbg transgene that contains the entire coding region together with
less than 1 kb upstream of the translation start site.
In both humans and human shbg transgenic mice, blood SHBG levels are low at birth, but
increase steadily with age until puberty, when a significant discrepancy occurs. While human
serum SHBG levels are generally higher in women than in men (Anderson, 1974; Vermeulen,
1988), the transgenic mice carrying a 11 kb human shbg fragment show a completely opposite
sexual dimorphism. This inconsistency could be explained by the absence of other regulatory
sequences not included in either shbg transgene, but might also be due to physiological differ-
ences between rodents and humans.
The fact that serum SHBG levels are not sexually dimorphic in mice carrying the 4 kb human
shbg transgene indicates that sequences upstream of the 4 kb fragment respond to repressor
signals in the female mouse liver. Whether this repression involves ovarian hormones waits for
further studies, but it appears that higher blood SHBG levels in transgenic males are not due to
direct effects of androgens, because castration has no effect on liver mRNA or serum SHBG
levels. However, any effects that sex hormones might have on SHBG production in these mice
can certainly be influenced by the unusual presence of very high amounts of SHBG in their
plasma.
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6.1.2 Transgenic mouse testis produces mainly alternative human shbg transcripts
Similar to the mouse endogenous shbg and rat shbg transgene (Joseph et al., 1997b; Larriba et
al., 1995), the 11 kb human shbg transgene is also active in the transgenic mouse testis. How-
ever, the transcription of human shbg in the testis of transgenic mice is under different regula-
tion than that in the liver, as evidenced by almost nonexistent testis-specific shbg expression in
mice carrying the 4 kb human shbg transgene. It appears that an entirely separate upstream
promoter controls shbg transcription in the testis and that the resulting transcripts lack exon 1
sequences including the translation start site utilized in the liver and kidney. The transcripts
derived from this tissue are therefore not likely to produce SHBG or ABP, as the first exon,
which is replaced by the alternative exon sequences in the testis, corresponds to the signal
sequence for secretion.
Variant shbg transcripts have been identified previously among the cDNAs isolated from a
human testis library (Hammond et al., 1989). Since the majority of these cDNAs represent
alternatively spliced gene products, it is not surprising that the expression of human shbg in the
transgenic mouse testis predominantly gives rise to alternative spliced variants.
The analysis of testicular human shbg gene products in transgenic mice is hampered by the
presence of immunoreactive SHBG derived from plasma, which probably accounts for the
signal seen in the interstitial compartment of both shbg11 and shbg4 animals. It is also possible
that available SHBG antibodies fail to recognize protein derived from these alternative tran-
scripts. Therefore, it is not yet known whether alternative transcripts produce functional pro-
tein, but it is tempting to speculate that such gene products serve a specific function in human
testis and several other tissues including female reproductive organs (Misao et al., 1997a,b,c,
1998a,b; Moore et al., 1996).
The lack of exon 1 sequences encoding the signal peptide probably results in the production of
an intracellular protein. Since these alternative transcripts often also lack exon 7, the steroid
binding property of the possible protein may deviate from that of plasma SHBG. An shbg gene
product with an alternate amino terminus has been characterized also in rats. Joseph et al.
demonstrated that such alternative mRNA encodes for an intracellular protein with a leader
sequence capable of targeting the gene product into the cell nucleus (Joseph et al., 1996). It was
hypothesized that this type of variant ABP/SHBG might locally regulate the sex steroid action
mediated by nuclear receptors.
Similar to the gene encoding rat ABP (Kierszenbaum et al., 1980; Anthony et al., 1984; Ritzen
et al., 1982), human shbg expression changes upon different stages of seminiferous epithelial
cycle. The rat gene can also be stimulated with androgens and FSH in vivo (Danzo, 1990,
1995), but whether human shbg is under similar control in the testis awaits further studies. In
any case, the alternative human shbg promoter seems to be activated even before the animals
reach sexual maturity and prior to increases in plasma testosterone, and is therefore most likely
regulated by mechanisms that do not necessarily involve sex steroids.
6.1.3 Human SHBG production in the transgenic mouse kidneys is regulated by an-
drogens
Human shbg expression in mouse kidney was somewhat surprising, because this tissue has not
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been reported to express shbg in humans. However, mouse endogenous shbg seems to be
active also in this tissue at low level (Jänne, Hogeveen and Hammond, unpublished data).
Being a very androgen-responsive tissue, kidney may represent an important, but so far ig-
nored site for shbg expression in humans.
The obvious rearrangement and lack of multiple copies of the transgene in shbg4-c mice com-
pared to other lines carrying the same human shbg fragment resulted in the lack of transgene
expression in kidney. Preliminary Southern blot analyses suggest that the possible rearrange-
ment occurred at the 3’-end of the transgene. Since the livers of these mice efficiently produce
SHBG, this region could be of interest as an enhancer required for kidney-specific human shbg
expression.
Similar to several other genes (Catterall et al., 1986), human shbg expression displays a signifi-
cant sexual dimorphism in the kidney, and unlike in the liver, this dimorphism was directly
linked to male sex steroids by castration and DHT administration experiments. Should the
human kidney also produce SHBG, it is possible that the androgen environment at a given time
determines the level of shbg expression to ensure locally the proper balance between free and
bound hormone.
6.2 Physiological consequences of human shbg expression in transgenic
mice
In spite of appreciable amounts of SHBG in transgenic mouse plasma, no obvious abnormali-
ties were observed in their reproductive performance. This was somewhat unexpected as it was
anticipated that the presence of SHBG would lead to imbalance in free and unbound steroids in
these rodents that normally do not have such large amounts of circulating sex steroid binding
protein in their plasma. Since the amount of free hormone was not measured, it is not known
whether SHBG occupies a significant fraction of sex steroids in the transgenic mouse serum.
However, considering the level of circulating SHBG, especially females might be expected to
have only trace amounts of free, biologically active estradiol in the blood. It seems therefore
doubtful that the sole function of SHBG is to passively restrict the access of sex steroids to
target tissues (Mendel, 1989). It could, for instance, release the bound steroids where needed
or act through membrane contacts that do not lead to specific signal propagation in mice.
Unpublished observations (Hodgert-Jury and Hammond) indicate that human SHBG accumu-
lates in certain steroid responsive mouse tissues such as uterine stroma, and that this accumula-
tion is steroid-dependent.
As more data is available about the possible actions of SHBG, it becomes evident that this
system regulating the actions of sex steroids is very diverse and yet more remains to be discov-
ered. Without doubt, cloning of the SHBG receptor is essential to fully confirm that the intrac-
ellular signaling cascades triggered by a steroid are mediated by an SHBG-receptor complex
(Fortunati et al., 1992, 1993; Nakhla et al., 1994, 1997; Frairia et al., 1992). These putative
actions have questioned the free hormone hypothesis, which may explain only a subset of the
actual functions of extracellular steroid binding proteins. Also, considering the similarity of the
receptor-binding region of SHBG with domains of several other proteins, novel and unexpected
functions for SHBG may be discovered in the future.
Although the shbg transgenic mice present an apparently normal phenotype, circulating SHBG
may cause subtle changes in physiological responses. Significantly elevated testosterone levels
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in transgenic animals may represent such situation, as the SHBG-bound testosterone in shbg
mice is probably resistant to metabolic clearance. It is also possible that the sex steroid-regu-
lated pituitary gonadotrophin secretion is modified in these mice due to an altered feedback
regulation by gonadal steroids.
Since kidney is an androgen-responsive tissue, renal SHBG production may influence the local
regulation of androgen action. However, studies on ornithine decarboxylase (ODC) and kidney
androgen-responsive protein (KAP) genes indicated that SHBG does not restrict the androgen
access to kidney, as these androgen-responsive genes are expressed at equal level in both hu-
man shbg transgenic and wild-type mouse kidneys (Bardin and Catterall, 1981; Crozat et al.,
1992) (Jänne and Hammond, unpublished results).
Any effects that possible testicular human shbg products may have in transgenic mice are very
subtle and do not compromise their reproductive performance. Mice transgenic for rat shbg
produce large amounts of ABP that is secreted from Sertoli cells and transported to epididymis
(Joseph et al., 1997b; Larriba et al., 1995). Infertility of these mice is probably due to increased
amounts of functional ABP in male reproductive organs, and may account for abnormalities in
the seminiferous tubule morphology and germ cell content (Joseph et al., 1997b; Larriba et al.,
1995). Since the majority of human shbg testicular transcripts in transgenic mice lack the se-
cretion signal associated with the SHBG precursor polypeptide, the functions of any resulting
gene products are likely to be intracellular.
6.3 Tissue-specificity of human and rodent shbg promoters.
Since the human shbg transgenes are active in the mouse liver, the lack of mouse endogenous
shbg expression by this organ is not due to the lack of necessary factors to support transcrip-
tion. It is also evident that promoter elements that respond to liver transcriptional activators are
present within a region immediately upstream of translation start site in exon 1 included in the
4 kb human shbg transgene. However, although the rodent and human genes are very homolo-
gous in their sequence immediately upstream of the translation start site in exon 1, a rat shbg
transgene containing 1.5 kb of 5’-flanking sequences is active in the testis but not in adult
mouse liver (Reventos et al., 1993).
In light of currently available data, it seems that homologous promoter regions in rodent and
human shbg drive the gene expression in different tissues. Interestingly, although adult mice
and rats do not have circulating SHBG, the gene is active in the fetal liver (Sullivan et al., 1991;
Becker and Iles, 1985). Since human shbg seems to be expressed in both fetal and adult mouse
liver, it is tempting to explain this paradox with a silencer mechanism such as that demon-
strated for the alpha-fetoprotein (AFP) gene. Comparable to rodent shbg, the AFP gene is
active in the fetal liver and its expression declines towards birth (Camper and Tilghman, 1989).
The promoter element responsible for this developmental silencing has been mapped upstream
of the transcription initiation site (Vacher and Tilghman, 1990). In support of this type of re-
pressive mechanism in terms of adult liver-specific shbg transcription in rodents, the mouse
proximal promoter is able to drive transcription from a luciferase reporter gene in cultured
hepatoma cells (Jänne and Hammond, unpublished results). This suggests that the region im-
mediately upstream of exon 1 serves as a liver-specific promoter in both humans and rodents.
In fact, the high-affinity HNF-4 binding site within human shbg FP1 is perfectly conserved in
rat and mouse genes. Whether the rat proximal shbg promoter is also able to support transcrip-
tion in liver cells is not known, but it is possible that a specific silencer represses the liver-
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specific promoter and prevents the production of circulating SHBG in adult rodents.
Unlike the human transgene comprising less than 1 kb of 5’-flanking sequences, a rat shbg
transgene is expressed at a high level in mouse testis (Joseph et al., 1997b; Larriba et al., 1995).
These transgenic mice also secrete ABP into epididymis, which indicates that 5’-flanking se-
quence and transcription unit corresponding to the human shbg liver-specific promoter is actu-
ally responsible for rat shbg expression in transgenic mouse testis. Characterization of the rat
shbg proximal promoter in vitro has demonstrated that it is active in cultured Sertoli cells, but
the evidence of testis-specific enhancer elements is still lacking (Fenstermacher and Joseph,
1997).
Whether an alternative promoter solely drives shbg expression in human testis is still unclear,
but it is possible that ABP found in rodent testis and epididymis does not play a significant role
in human reproductive biology. The fact that rabbits have both plasma SHBG and testicular
ABP suggests, however, that one of the protein homologs does not exclude the presence of the
other (Cheng et al., 1984).
6.4 Human shbg expression is regulated by HNF-4 in liver cells
In humans, plasma SHBG levels are regulated by different physiological and pathological con-
ditions as well as by nutritional status and body mass (Pugeat et al., 1995; Reed et al., 1987;
Lapidus et al., 1986; Vermeulen, 1988). Hepatic SHBG production has also been studied in
cultured cells (Rosner et al., 1984; Loukovaara et al., 1995a,b,c; Plymate et al., 1988), but little
is known about the transcriptional regulation of the gene.
Human and rat shbg genes have been referred to as TATA-less genes, because neither contains
a consensus TATA-sequence in close proximity to the tissue-specific transcription start sites
(Joseph et al., 1988). Although the human shbg promoter contains a TATA-like sequence at -30
relative to the transcription start site in the liver, the present data suggest that TBP does not
mediate transcriptional activation through this element. Instead, the promoter region spanning
the TA-rich proximal sequence binds two orphan members of the nuclear receptor superfamily
present in mouse liver nuclear extract. Of the two orphan receptors, only HNF-4 appears to
transactivate the human shbg promoter, and this transactivation can be blunted by overexpression
of COUP-TF.
Both COUP-TF and HNF-4 bind DNA as dimers, and while COUP-TF has several dimeriza-
tion partners (Berrodin et al., 1992), HNF-4 forms exclusively homodimers (Jiang et al., 1995).
Therefore, antagonism between these factors at human shbg FP1 could be mediated through a
common binding site in the DNA motif. However, since both COUP-TF and HNF-4 also inter-
act with general transcription factors (Malik and Karathanasis, 1996; Hadzopoulou-Cladaras
et al., 1997), these interactions could determine the relative effectiveness of each orphan recep-
tor to activate human shbg promoter. For instance, ATF transactivation domain of HNF-4 has
been shown to recruit TFIIB to the ApoA1 promoter, thereby influencing the entry of the
preinitiation complex followed by transcriptional activation (Malik and Karathanasis, 1996).
The FP1 sequence within the human shbg promoter is well conserved in rat shbg promoter, and
could therefore represent an important element for liver-specific transcription in both species
(Figure 10).
Although COUP-TF and HNF-4 also bind to FP3 within the human shbg proximal promoter,
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FP1 seems to be more important in mediating basal transcriptional activity in hepatoma cells in
vitro. FP3, which shows a relatively weak responsiveness to HNF-4 overexpression in cells,
could play a yet unidentified role in human shbg expression during specific situations. The
availability of a natural ligand, through influencing the conformational state of COUP-TF and
HNF-4, may further modulate the promoter activity in different tissues. Long chain fatty acyl-
CoA thioesters have been shown to enhance the dimerization and transactivation capacity of
HNF-4 (Hertz et al., 1998), but a ligand activating COUP-TF is yet to be found. The involve-
ment of fatty acids in the regulation of shbg could explain the variations of plasma SHBG
levels in certain human physiological and pathological conditions, such as obesity (Reed et al.,
1987; Lapidus et al., 1986; Vermeulen, 1988).
HNF-4 regulates several other liver-specific genes, such as the one encoding factor X. A single
nucleotide change within the factor X promoter disrupts the binding of HNF-4 and leads to
decreased plasma factor X levels and hemophilia B (Reijnen et al., 1992). Plasma SHBG has
also been linked to some diseases. For instance, low plasma SHBG has been recognized as an
early indicator of maturity onset diabetes of the young (MODY) (Rudberg and Persson, 1995).
Recently, the DNA mutation that causes this disease was mapped to HNF-4 locus (Yamagata et
al., 1996), and this mutation was shown to indirectly cause pancreatic beta cell dysfunction and
diabetes. The identification of HNF-4 as a regulator of liver-specific shbg expression could
thus form a link between diabetes and low plasma SHBG. Moreover, the gene encoding HNF-
4 is also expressed in the kidney and intestine (Sladek, 1994) consistent with the human shbg
expression in adult and fetal mice, respectively. These data provide evidence for the regulation
of human shbg expression by HNF-4 also in vivo.
6.5 Silencing of human shbg promoter
Although the human shbg transgene that extends up to -803 nts from the transcription start site
is active in the transgenic mouse liver, the sequences upstream of -299 repress transcription
when placed in front of a luciferase reporter gene in vitro.
It is evident that the Alu repeats at -727/-697 in the human shbg promoter bind a factor that
represses transcription, as the removal of these sequences partially recovers the promoter ac-
tivity. The characterization of this factor is under way, but preliminary analyses indicate that
there are multiple complexes involved in this silencing.
Figure 10. Proposed mechanism for transcriptional intiation from the human shbg promoter. HNF-4 controls
transcription initiation by substituting TATA-binding protein (TBP) and recruiting  the transcription initiation com-
plex (TAFs, TFIIB (IIB), TFIIF (IIF), TFIIE (IIE), and TFIIH (IIH)).
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In support of a physiological role for the more distal TA-rich sequence within the human shbg
promoter, there is a polymorphism with respect to the number of TAAAA repeats among ge-
nomic DNA samples from different individuals (Hogeveen and Hammond, unpublished re-
sults). However, since the DNA samples that were screened were derived from patients with
variable health status, i.e. obesity and hirsutism (Pugeat et al., 1996), it has not yet been pos-
sible to evaluate the significance of this polymorphism.
In the context of other genes, Sp1 has been shown to participate in specific recruitment of other
transcription factors (Wood et al., 1996; Kim et al., 1999). It is therefore of interest that the
mutation within Sp1 binding site increases the activity of the human shbg promoter without
completely rescuing it. However, even though Sp1 binds to shbg promoter in vitro, it is more
likely that the protein interacting with this site in intact cells is indeed a repressor, such as Sp3
or WT-1 also belonging to the same protein family (Philipsen S. and Suske G., 1999).The
factor binding to the TA-rich silencer further upstream could then rely on Sp1-related factor on
the recruitment to the promoter, but the significance of such interactions is yet to be proved.
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